AA
AURA icon

ALPS Advisors’s Aura Biosciences AURA Stock Holding History

ALPS Advisors’s Portfolio AURA Stock Details AURA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-37,156
Closed -$218K – 1031
2025
Q1 		$218K Sell
37,156
-3,236
-8% -$24.5K ﹤0.01% 957
2024
Q4 		$332K Buy
40,392
+5,181
+15% +$48.8K ﹤0.01% 830
2024
Q3 		$314K Sell
35,211
-3,440
-9% -$29.5K ﹤0.01% 948
2024
Q2 		$292K Buy
38,651
+3,955
+11% +$29K ﹤0.01% 858
2024
Q1 		$272K Buy
34,696
+1,036
+3% +$8.59K ﹤0.01% 920
2023
Q4 		$298K Buy
33,660
+5,501
+20% +$46.6K ﹤0.01% 857
2023
Q3 		$253K Buy
28,159
+372
+1% +$4K ﹤0.01% 912
2023
Q2 		$343K Buy
27,787
+4,043
+17% +$43.2K ﹤0.01% 751
2023
Q1 		$220K Sell
23,744
-688
-3% -$7.15K ﹤0.01% 977
2022
Q4 		$257K Buy
+24,432
New +$311K ﹤0.01% 953

Other funds holding AURA

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

ALPS Advisors's AURA Position: Q2 2025 in Review

ALPS Advisors sold out of Aura Biosciences (AURA) in Q2 2025, closing a stake of 37,156 shares — an estimated $218K sold.

ALPS Advisors first reported a position in AURA in Q4 2022 and held it in 10 quarters. The position peaked at $343K in Q2 2023. 104 funds tracked by Wall St. Rank hold AURA as of Q2 2025.

  • ALPS Advisors reported no remaining Aura Biosciences position as of Q2 2025 after selling out during the quarter.
  • ALPS Advisors sold 37,156 Aura Biosciences shares in Q2 2025, an estimated $218K.
  • ALPS Advisors first reported a position in Aura Biosciences in Q4 2022 and held it in 10 quarters.
  • ALPS Advisors's Aura Biosciences position peaked at $343K in Q2 2023.
  • 104 funds tracked by Wall St. Rank held Aura Biosciences as of Q2 2025.

Based on ALPS Advisors's 13F filing for Q2 2025, filed 11 Aug 2025.